RRM2B
ENSG00000048392
Target class
Enzyme
Chromosome
8
Approved drugs
5
Clinical candidates (approved and in development)
8
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Other names
- p53R2
- Target name
- RRM2B
- Gene name
- Ribonucleotide reductase regulatory TP53 inducible subunit M2B
- Gene symbol
- RRM2B
- Protein name
- Ribonucleoside-diphosphate reductase subunit M2 B (EC 1.17.4.1) (TP53-inducible ribonucleotide reductase M2 B) (p53-inducible ribonucleotide reductase small subunit 2-like protein) (p53R2)
- Gene biotype
- Protein coding
- Gene family
- Ribonucleotide reductase subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 35.21
- Tissue specificity (Gini)
- 0.245
- Tissue specificity (tau)
- 0.646
- KEGG gene identifiers
- hsa:50484
- Protein interaction confidence
- 0.847429
- Protein interaction partners
- 56
- R-HSA-499943
- R-HSA-5628897
- End position
- 102239382
- Start position
- 102204502
- Chromosome
- 8
- Strand
- Reverse
- Cytoplasm. Nucleus. Note=Translocates from cytoplasm to nucleus in response to DNA damage.
- Cytosol
- Nucleoplasm
- Tissue specificity (tau)
- 0.646005
- Expression inequality (Gini)
- 0.244799
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 35.21
- Thyroid
- 33.12
- Cells - Cultured fibroblasts
- 25.45
- Artery - Aorta
- 21.97
- Lung
- 20.72
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes35.21
- Thyroid33.12
- Cells - Cultured fibroblasts25.45
- Artery - Aorta21.97
- Lung20.72
- Pituitary20.44
- Muscle - Skeletal20.37
- Adrenal Gland18.93
- Artery - Coronary18.85
- Brain - Spinal cord (cervical c-1)17.03
- Artery - Tibial15.93
- Nerve - Tibial15.57
- Ovary15.07
- Prostate14.71
- Cervix - Endocervix14.66
- Fallopian Tube14.37
- Uterus14.3
- Adipose - Subcutaneous13.96
- Cervix - Ectocervix13.91
- Brain - Frontal Cortex (BA9)13.52
- Bladder13.08
- Esophagus - Muscularis12.76
- Colon - Sigmoid12.18
- Esophagus - Gastroesophageal Junction12.09
- Brain - Substantia nigra11.86
And 29 more, listed on the interactive page.
- GO:0006264
- GO:0006281
- GO:0009185
- GO:0009265
- GO:0010971
- GO:0070318
- GO:0005654
- GO:0005829
- GO:0005515
- GO:0042802
Related records
Trials (4,971)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Drugs (10)
- Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Fludarabine phosphate Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gallium nitrate Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gemcitabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor
- Hydroxyurea Ribonucleoside-diphosphate reductase RR1 inhibitor
- Motexafin gadolinium Ribonucleoside-diphosphate reductase RR1 inhibitor
- Tezacitabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Tezacitabine anhydrous Ribonucleoside-diphosphate reductase RR1 inhibitor
- Triapine Ribonucleotide reductase inhibitor